Other Current Liabilities |
6 Months Ended | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Jun. 30, 2026 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Other Liabilities, Current [Abstract] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Other Current Liabilities | 9. OTHER CURRENT LIABILITIES
(1) In September 2025, the Group entered into an agreement with TJ Biopharma to facilitate the sale of the Group’s holding of TJ Biopharma’s preferred shares, whereby TJ Biopharma paid the Group a cash deposit. See the Company’s Annual Report for additional information. (2) Represents the current portion of the non-contingent quarterly payments related to the Bridge Health acquisition. See Note 4 – Asset Acquisitions and Strategic Transactions for additional information. |
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||